[go: up one dir, main page]

ES2155535T3 - Inhibidores de sintesis de apoliproteina b. - Google Patents

Inhibidores de sintesis de apoliproteina b.

Info

Publication number
ES2155535T3
ES2155535T3 ES95937804T ES95937804T ES2155535T3 ES 2155535 T3 ES2155535 T3 ES 2155535T3 ES 95937804 T ES95937804 T ES 95937804T ES 95937804 T ES95937804 T ES 95937804T ES 2155535 T3 ES2155535 T3 ES 2155535T3
Authority
ES
Spain
Prior art keywords
sub
rent
sup
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95937804T
Other languages
English (en)
Inventor
Jan Heeres
Leo Jacobus Jozef Backx
Robert Jozef Maria Hendrickx
Der Eycken Luc Alfons Leo Van
Chaffoy De Courcelles Didie De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/455,304 external-priority patent/US5521186A/en
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2155535T3 publication Critical patent/ES2155535T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION, PROPORCIONA NUEVOS COMPUESTOS DE FORMULA (I), N-OXIDOS, FORMAS ESTEREOQUIMICAMENTE ISOMERICAS, Y SALES DE ADICION ACIDAS, FARMACEUTICAMENTE ACEPTABLES, DE LOS MISMOS. EN LA FORMULA (I), A Y B, UNIDOS, FORMAN UN RADICAL BIVALENTE DE FORMULA: -N=CH- (A), -CH=N- (B), CH{SUB,2}-CH{SUB,2}- (C), CH=CH- (D), -C(=O)-CH{SUB,2}- (E), -CH{SUB,2}-C(=O)- (F); R{SUP,1} ES HIDROGENO, ALQUILO C{SUB,1-6}, O HALO; R{SUP,2} ES HIDROGENO O HALO; R{SUP,3} ES HIDROGENO; ALQUILO C{SUB,1-8}, CICLOALQUILO C{SUB,3-6} O ALQUILO C{SUB,1-8} SUSTITUIDO CON HIDROXI, OXO, CICLOALQUILO C{SUB,3-6} O ARILO. HET ES UN ANILLO HETEROCICLICO DE CINCO O SEIS MIEMBROS, OPCIONALMENTE SUSTITUIDO. SE DESCRIBE ASIMISMO SU UTILIZACION COMO MEDICINA, ESPECIALMENTE COMO AGENTE REDUCTOR DE LIPIDOS, ASI COMO LAS COMPOSICIONES FARMACEUTICAS Y PROCEDIMIENTOS DE PREPARACION DE DICHOS COMPUESTOS Y COMPOSICIONES.
ES95937804T 1994-10-27 1995-10-19 Inhibidores de sintesis de apoliproteina b. Expired - Lifetime ES2155535T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203120 1994-10-27
US08/455,304 US5521186A (en) 1994-10-27 1995-05-31 Apolipoprotein-β synthesis inhibitors

Publications (1)

Publication Number Publication Date
ES2155535T3 true ES2155535T3 (es) 2001-05-16

Family

ID=26136684

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95937804T Expired - Lifetime ES2155535T3 (es) 1994-10-27 1995-10-19 Inhibidores de sintesis de apoliproteina b.

Country Status (30)

Country Link
US (1) US5929075A (es)
EP (1) EP0788496B1 (es)
JP (1) JP3025907B2 (es)
KR (1) KR100227231B1 (es)
CN (1) CN1068000C (es)
AP (1) AP779A (es)
AT (1) ATE198889T1 (es)
AU (1) AU697744C (es)
BG (1) BG63694B1 (es)
BR (1) BR9509436A (es)
CA (1) CA2203274C (es)
CY (1) CY2256B1 (es)
CZ (1) CZ286476B6 (es)
DE (3) DE122007000005I2 (es)
DK (1) DK0788496T3 (es)
ES (1) ES2155535T3 (es)
FI (1) FI119548B (es)
GR (1) GR3035519T3 (es)
HR (1) HRP950532B1 (es)
HU (1) HU219862B (es)
IL (1) IL115771A (es)
LU (1) LU91306I2 (es)
NO (1) NO311937B1 (es)
NZ (1) NZ295353A (es)
OA (1) OA10479A (es)
PT (1) PT788496E (es)
RO (1) RO118715B1 (es)
SK (1) SK281908B6 (es)
TR (1) TR199501295A2 (es)
WO (1) WO1996013499A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2307097A1 (en) 1997-11-03 1999-05-14 Janssen Pharmaceutica N.V. Compositions of lipid lowering agents
CN1308523A (zh) * 1998-04-27 2001-08-15 詹森药业有限公司 含有用降脂剂和聚合物包衣的丸芯的微丸
JP2002533339A (ja) * 1998-12-22 2002-10-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｓ−オキシドの脂質降下化合物
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US20050132022A1 (en) * 2003-12-12 2005-06-16 International Business Machines Corporation Computer system with LAN-based I/O
EP1708680A2 (en) * 2004-01-21 2006-10-11 Janssen Pharmaceutica N.V. Mitratapide oral solution
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
CA2562015A1 (en) * 2004-04-09 2005-10-20 Janssen Pharmaceutica Nv Intermittent dosing regimens of apob secretion/mtp inhibitors for overweith and obese subjects
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
JP2009503050A (ja) * 2005-08-04 2009-01-29 ファイザー・リミテッド ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
BRPI0708264A2 (pt) * 2006-02-23 2011-05-24 Pfizer Ltd piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
ATE474836T1 (de) 2007-05-25 2010-08-15 Janssen Pharmaceutica Nv Verbesserte synthese von (2s-cis)-2-(brommethyl)- 2-(4-chlorphenyl)-1,3-dioxolan-4-methanol- methansulfonat(ester)
MX2011001405A (es) * 2008-08-06 2011-03-21 Pfizer Ltd Compuestos de diazepina y diazocano como agonistas de mc4.
BR112012029227B1 (pt) * 2010-05-19 2020-01-07 Sandoz Ag Processo para a preparação de um composto quiral, composto quiral e uso de um composto
CN112074505B (zh) 2018-03-08 2024-04-05 因赛特公司 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313953A (en) * 1978-06-23 1982-02-02 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
AU6359594A (en) * 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors

Also Published As

Publication number Publication date
CN1068000C (zh) 2001-07-04
KR100227231B1 (ko) 1999-11-01
IL115771A (en) 2000-02-29
FI971784L (fi) 1997-04-25
CA2203274A1 (en) 1996-05-09
JPH09511759A (ja) 1997-11-25
US5929075A (en) 1999-07-27
CY2256B1 (en) 2003-07-04
DE69519995D1 (en) 2001-03-01
IL115771A0 (en) 1996-01-19
TR199501295A2 (tr) 1996-06-21
CZ119897A3 (cs) 1998-03-18
HUT77360A (hu) 1998-03-30
DE122007000005I1 (de) 2007-04-26
AU697744B2 (en) 1998-10-15
BG63694B1 (bg) 2002-09-30
CA2203274C (en) 2002-02-19
WO1996013499A1 (en) 1996-05-09
SK281908B6 (sk) 2001-09-11
NO971895L (no) 1997-04-24
BG101402A (en) 1997-10-31
HRP950532B1 (en) 2001-06-30
DE69519995T2 (de) 2001-08-23
NO311937B1 (no) 2002-02-18
NZ295353A (en) 1998-08-26
DK0788496T3 (da) 2001-06-18
PT788496E (pt) 2001-07-31
EP0788496A1 (en) 1997-08-13
MX9703074A (es) 1997-07-31
AP779A (en) 1999-11-03
RO118715B1 (ro) 2003-09-30
ATE198889T1 (de) 2001-02-15
AU3868095A (en) 1996-05-23
SK50797A3 (en) 1998-04-08
FI971784A0 (fi) 1997-04-25
LU91306I2 (fr) 2007-03-19
JP3025907B2 (ja) 2000-03-27
FI119548B (fi) 2008-12-31
BR9509436A (pt) 1998-01-06
HU219862B (hu) 2001-08-28
EP0788496B1 (en) 2001-01-24
AP9700968A0 (en) 1997-04-30
DE122007000005I2 (de) 2008-04-24
AU697744C (en) 2002-08-22
OA10479A (en) 2002-04-09
CN1161695A (zh) 1997-10-08
GR3035519T3 (en) 2001-06-29
CZ286476B6 (en) 2000-04-12
HRP950532A2 (en) 1997-08-31
NO971895D0 (no) 1997-04-24

Similar Documents

Publication Publication Date Title
ES2155535T3 (es) Inhibidores de sintesis de apoliproteina b.
ES2084944T3 (es) Amidas terapeuticas.
ES8603870A1 (es) Un procedimiento para la preparacion de derivados de 2,2'-iminobisetanol.
NO163956C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive (4-piperidinylmetyl- og -hetero)puriner.
ES8706668A1 (es) Un procedimiento para la preparacion de derivados de piperidina.
DK0378255T3 (da) 2-aminopyrimidinoderivater
ES539658A0 (es) Procedimiento de preparacion de nuevos derivados de la xan- tina y de sus sales de adicion con acidos apropiados
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
AR018033A1 (es) Analogos 13-oxa prostaglandinas, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
NO172580C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte n-(1-alkyl-3-hydroksy-4-piperidinyl)benzamider
ES2058749T3 (es) Derivados 2-aminopirimidinona.
ATE2265T1 (de) Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
NO167803C (no) Analogifremgangsmaate til fremstilling av terapeutiskordskilleaktive n-(4-piperidinyl)bicyklisk kondenserte 2-imidazolaminderivater.
EA200500882A1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
NO912888D0 (no) Fremgangsmaate for fremstilling av nye peperidylethere og -thioethere.
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
MX9206614A (es) Derivados de ariletanolamina, proceso para su preparacion y composicion farmaceutica que los contiene
DK434789D0 (da) 3-piperidinyl-indazolderivater, fremgangsmaade til fremstilling deraf samt praeparater indeholdende samme
NO164474C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heksahydropyrrolo(2,1-a)isokinolin-derivater.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 788496

Country of ref document: ES